跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

A0325200

Alcuronium chloride

European Pharmacopoeia (EP) Reference Standard

别名:

N,N′-Diallylnortoxiferinium dichloride

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C44H50Cl2N4O2
CAS号:
分子量:
737.80
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

alcuronium

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

−20°C

SMILES字符串

[Cl-].[Cl-].[N+]21([C@@H]3C4([C@H]5N(c%11c4cccc%11)\C=C6/[C@@H]7N(c8c(cccc8)C97[C@H]%10[N+](CC9)(C\C(=C\CO)\C/6C%10)CC=C)\C=C/5\C(C3)\C(=C/CO)\C2)CC1)CC=C

InChI

1S/C44H50N4O2.2ClH/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49;;/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2;2*1H/q+2;;/p-2/b29-13-,30-14-,33-25-,34-26-;;/t31?,32?,39-,40-,41-,42-,43?,44?,47?,48?;;/m0../s1

InChI key

CPYGBGOXCJJJGC-ZHNYPADJSA-L

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Alcuronium chloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbones

警示用语:

Danger

危险声明

预防措施声明

危险分类

Acute Tox. 2 Oral

储存分类代码

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

C Tränkle et al.
The Journal of pharmacology and experimental therapeutics, 279(2), 926-933 (1996-11-01)
Various compounds are known to allosterically modulate the binding of ligands to muscarinic receptors. Most of these compounds have another predominant pharmacological action. Identification of the potent representatives should be useful for the development of allosteric modulators that are specific
A Lanzafame et al.
The Journal of pharmacology and experimental therapeutics, 282(1), 278-285 (1997-07-01)
Functional studies were conducted on guinea pig atrial muscarinic acetylcholine M2 receptors with the allosteric modulators heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide (C7/3'-phth), gallamine and alcuronium to determine whether these ligands are able to recognize a common accessory site. The three modulators inhibited the
Lauren T May et al.
The Journal of pharmacology and experimental therapeutics, 312(1), 382-390 (2004-08-31)
The effects of prolonged exposure of M(2) muscarinic acetylcholine receptors (mAChRs), stably expressed in Chinese hamster ovary cells, to the allosteric modulators gallamine, alcuronium, and heptane-1,7-bis (dimethyl-3'-phthalimidopropyl)-ammonium bromide (C(7)/3'-phth) were compared with the effects of the agonist carbachol (CCh) and
Terry Kenakin
Receptors & channels, 10(2), 51-60 (2004-06-19)
Allosterism, whereby small molecule ligands produce global changes in the conformations of receptors, is a powerful mechanism for drug effect. This is illustrated by the recent data describing CCR5 antagonists as blockers of HIV infection. Allosteric effects are described in
A Christopoulos et al.
Clinical and experimental pharmacology & physiology, 25(3-4), 185-194 (1998-05-20)
1. An allosteric interaction occurs when the binding of a ligand to its site on a receptor is able to modify the binding of another ligand to a topographically distinct site on the same receptor and vice versa. The muscarinic

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门